Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040
The report offers actions to overcome the barriers that have blocked progress in achieving health equity across HIV, STIs, & COVID-19
-
GSK to showcase significant scientific advances in renal care at the American Society of Nephrology Kidney Week 2021
Data from all five Phase 3 trials of the ASCEND programme for the investigational medicine daprodustat will be presented at the meeting.
-
ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV
Paediatric HIV remains a global issue, with children disproportionately affected by the HIV epidemic.
-
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
Final FDA decision anticipated by 24 January 2022; if approved, cabotegravir would be the first long-acting therapy for HIV PrEP
-
ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals
S-365598 aims to build on the success of dolutegravir & cabotegravir with potential to anchor the next-gen pipeline of HIV therapies
-
Changing attitudes to vaccination after the COVID-19 pandemic could increase adult vaccination rates, improving health outcomes over the longer term
Survey shows that people 50 years of age and older value good health and improved quality of life.
-
ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021
ViiV Healthcare announce the presentation of 13 abstracts from its portfolio of pipeline prevention options.
-
GSK announces major renewable energy investment and low carbon inhaler programme alongside Life Sciences sector Race to Zero ‘breakthrough’ at NYC Climate Week
Company announces £50m investment in renewable energy and carbon reduction at major UK and US manufacturing sites.
-
GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO
GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO
-
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data
-
GSK announces “Ask2BSure” public health awareness campaign for meningitis B vaccination
GSK launches “Ask2BSure,” to encourage parents to talk with their child’s doctor to be sure if they have received meningitis B vaccination.
-
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors
GSK receives FDA accelerated approval for JEMPERLI for adult patients with mismatch repair-deficient recurrent or advanced solid tumors
-
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone
-
GSK files for licensure of MMR vaccine in the US
GSK seeks US approval of PRIORIX vaccine licensed in more than 100 countries.
-
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
Fourth indication for mepolizumab in the US for eosinophil-driven diseases.
-
GSK delivers strong Q2 sales of £8.1 billion, +6% AER, +15% CER Total EPS 27.9p -39% AER, -28% CER; Adjusted EPS 28.1p +46% AER +71% CER
Sales growth driven by strong commercial execution and favourable prior year comparison
-
Shingrix approved in the US for prevention of shingles in immunocompromised adults
Shingrix approved in the US for prevention of shingles in immunocompromised adults
-
GSK begins shipping another record supply of influenza vaccine for 2021-22 season in US
GSK increases its volume of influenza vaccines in 2021 to support immunization during pandemic.
-
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
ViiV Healthcare today presented 48-week data from the SALSA study at the International AIDS Society Conference 2021
-
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
ViiV Healthcare today presented positive findings from the CUSTOMIZE trial
